Dimerix Ltd has released a press release.
FDA IND Approval for Phase 3 Study of DMX-200 in FSGS
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Dimerix
- Dimerix Receives A$3.7M R&D Tax Incentive Rebate
- DSMB Change to REMAP-CAP COVID-19 Study
- Half-Year Financial Report & Appendix 4D - 31 December 2021
- First Regulatory Approval in Europe for DMX-200 FSGS Study
- Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
Later from Dimerix
- Dimerix presentation at Bioshares Biotech Summit
- Phase 3 FSGS Kidney Trial First Patient Recruited
- New Clinical Trial for DMX-200 in Diabetic Kidney Disease
- REMAP-CAP COVID-19 Study Analysis Update
- DMX-700 Study Shows Significant 80% Reduction in Lung Injury
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix